Literature DB >> 23625322

Bevacizumab versus ranibizumab: why are we not playing the joker?

Roberto Banfi, Francesco Attanasio, Nadia Palazzi, Silvia Colombini, Tiziana Falai, Michele Cecchi, Gianni Virgili.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23625322     DOI： 10.1007/s11096-013-9779-7

Source DB:  PubMed          Journal:  Int J Clin Pharm


× No keyword cloud information.
  13 in total

Review 1.  [Social pharmacology: a new topic in clinical pharmacology].

Authors:  J L Montastruc
Journal:  Therapie       Date:  2002 Sep-Oct       Impact factor: 2.070

2.  Off-label prescribing in macular degeneration.

Authors:  Margaret McCartney
Journal:  BMJ       Date:  2011-10-19

3.  5.7 Times more expensive than liquid gold.

Authors:  Gordon S Bowler; Tessa Fayers; Pieter Gouws
Journal:  Br J Ophthalmol       Date:  2011-11-28       Impact factor: 4.638

4.  Anti-vascular endothelial growth factor treatment for eye diseases.

Authors:  Ning Cheung; Dennis S C Lam; Tien Y Wong
Journal:  BMJ       Date:  2012-05-01

5.  Why using Avastin for eye disease is so difficult.

Authors:  Ingrid Torjesen
Journal:  BMJ       Date:  2012-05-01

6.  CATT: Into the eye of a tiger.

Authors:  Jonathan Sears; James Bena; Arun D Singh
Journal:  Br J Ophthalmol       Date:  2011-06       Impact factor: 4.638

7.  Avastin doesn't blind people, people blind people.

Authors:  Serafin Gonzalez; Philip J Rosenfeld; Michael W Stewart; Jennifer Brown; Steven P Murphy
Journal:  Am J Ophthalmol       Date:  2012-02       Impact factor: 5.258

8.  Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing.

Authors:  Sophie J Bakri; Melissa R Snyder; Jose S Pulido; Colin A McCannel; William T Weiss; Ravinder J Singh
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

9.  Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration.

Authors:  M Paul; V Vieillard; E Roumi; A Cauvin; M C Despiau; M Laurent; A Astier
Journal:  Ann Pharm Fr       Date:  2012-05-11

10.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245
View more
  2 in total

1.  Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.

Authors:  Gianni Virgili; Mariacristina Parravano; Jennifer R Evans; Iris Gordon; Ersilia Lucenteforte
Journal:  Cochrane Database Syst Rev       Date:  2018-10-16

Review 2.  Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.

Authors:  Bin Wu; Haixiang Wu; Xiaoyan Liu; Houwen Lin; Jin Li
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.